| Pharmaceutical Information |
| Drug Name |
Ropinirole hydrochloride |
| Drug ID |
BADD_D01967 |
| Description |
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547].
In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711]. |
| Indications and Usage |
For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome [FDA label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
N04BC04 |
| DrugBank ID |
DB00268
|
| KEGG ID |
D00784
|
| MeSH ID |
C046649
|
| PubChem ID |
68727
|
| TTD Drug ID |
D0R9EQ
|
| NDC Product Code |
43547-269; 43547-270; 43547-599; 65841-716; 70518-2476; 54752-0005; 43547-597; 43547-598; 46708-033; 50090-4348; 62332-036; 63629-4641; 0615-8188; 0904-6373; 43547-596; 46708-031; 46708-032; 50268-743; 55154-7633; 55154-7888; 61919-564; 65841-714; 71335-1626; 0615-8190; 65841-718; 65096-0102; 43547-271; 62332-033; 62332-034; 65841-715; 71335-1434; 0615-8189; 62147-0015; 43547-595; 46708-030; 46708-035; 62332-035; 61187-008; 62147-0008; 64220-121; 43547-273; 50090-1330; 60687-588; 62332-030; 63629-4798; 71335-0727; 0904-6374; 43547-272; 46708-036; 62332-032; 71335-0587; 71335-0829; 0615-8191; 43547-274; 43547-600; 50268-742; 50268-744; 62332-031; 55111-091; 46708-034; 60687-577; 65841-712; 65841-713; 65841-717; 58032-0133; 66039-853; 43547-268; 43547-601; 50268-741 |
| UNII |
D7ZD41RZI9
|
| Synonyms |
ropinirole | 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone | ropinirol | SK&F 101468 | SKF 101468 | SK&F-101,468 | Requip | ropinirole hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C16H25ClN2O |
| CAS Registry Number |
91374-20-8 |
| SMILES |
CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Psychotic disorder | 19.03.01.002 | - | - | |
|
|
|
